Molecular Interrogation Of Circulating Tumor Cells For Drug Development In Breast Cancer

 
Published on March 27, 2017

Aditya Bardia, MD, MPH, Massachusetts General Hospital Cancer Center, Harvard Medical School Circulating tumor cells (CTCs) can serve as potential “liquid biopsies” offering a potential relatively non-invasive tool for monitoring of breast cancer. In partnership with the laboratory of Dr. Mehmet Toner (MGH Center for Bioengineering in Medicine), Dr. Daniel Haber et al. recently developed a nanotechnology micropost-based microfluidic device, the “CTC-ichip”, specifically designed to accurately capture rare and delicate CTCs out of whole blood, following processing through a low shear flow chamber.